

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>	Application Number		10810919
	Filing Date		2004-03-26
	First Named Inventor		Wisniewski et al.
	Art Unit		1649
	Examiner Name		Olga N. Chernyshev
	Attorney Docket Number		57953/1211

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS							
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1						

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					

T5

□

T5

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /OC/

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10810919
Filing Date	2004-03-26
First Named Inventor	Wisniewski et al.
Art Unit	1649
Examiner Name	Olga N. Chernyshev
Attorney Docket Number	57953/1211

1	BALES et al., "Apolipoprotein E is Essential for Amyloid Deposition in the APPV717F Transgenic Mouse Model of Alzheimer's Disease," Proc. Natl. Acad. Sci. (USA) 96:15233-15238 (1999)	<input type="checkbox"/>
2	BALES et al., "Lack of Apolipoprotein E Dramatically Reduces Amyloid Beta-Peptide Deposition," Nature Gen. 17:263-264 (1997)	<input type="checkbox"/>
3	BARROW et al., "Solution Conformations and Aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra," J. Mol. Biol. 225:1075-1093 (1992)	<input type="checkbox"/>
4	BUTTINI et al., "Modulation of Alzheimer-Like Synaptic and Cholinergic Deficits in Transgenic Mice by Human Apolipoprotein E Depends on Isoform, Aging and Overexpression of Amyloid Beta Peptides but not on Plaque Formation," J. Neurosci. 22:10539-10548 (2002)	<input type="checkbox"/>
5	CASTANO et al., "Fibrillogenesis in Alzheimer's Disease of Amyloid Beta Peptides and Apolipoprotein E," Biochem. J. 306:599-604 (1995)	<input type="checkbox"/>
6	DEMATTOS et al., "ApoE and Clusterin Cooperatively Suppress ABeta Levels and Deposition: Evidence that ApoE Regulates Extracellular ABeta Metabolism In Vivo," Neuron 41:193-202 (2004)	<input type="checkbox"/>
7	GOLABEK et al., "Amyloid Beta Binding Proteins In Vitro and In Normal Human Cerebrospinal Fluid," Neurosci. Lett. 191:79-82 (1995)	<input type="checkbox"/>
8	GOLABEK et al., "The Interaction Between Apolipoprotein E and Alzheimer's Amyloid Beta-peptide is Dependent on Beta-Peptide Conformation," J. Biol. Chem. 271:10602-10606 (1996)	<input type="checkbox"/>
9	HOLTZMAN et al., "Apolipoprotein E Isoform-Dependent Amyloid Deposition and Neuritic Degeneration in a Mouse Model of Alzheimer's Disease," Proc. Natl. Acad. Sci. (USA) 97:2892-2897 (2000)	<input type="checkbox"/>
10	HOLTZMAN et al., "Expression of Human Apolipoprotein E Reduces Amyloid-Beta Deposition in a Mouse Model of Alzheimer's Disease," J. Clin. Invest. 103:R15-R21 (1999)	<input type="checkbox"/>
11	JI et al., "Amyloid Beta40/42 Clearance Across the Blood-Brain Barrier Following Intra-Ventricular Injections in Wild-Type, ApoE Knock-Out and Human ApoE3 or E4 Expressing Transgenic Mice," J. Alz. Dis. 3:23-30 (2001)	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /OC/

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10810919
Filing Date	2004-03-26
First Named Inventor	Wisniewski et al.
Art Unit	1649
Examiner Name	Olga N. Chernyshev
Attorney Docket Number	57953/1211

12	JI et al., "Apolipoprotein E Isoform-Specific Regulation of Dendritic Spine Morphology in Apolipoprotein E Transgenic Mice and Alzheimer's Disease Patients," <i>Neuroscience</i> 122:305-315 (2003)	<input type="checkbox"/>
13	MA et al., "Alzheimer ABeta Neurotoxicity: Promotion by Antichymotrypsin, ApoE4; Inhibition by ABeta-Related Peptides," <i>Neurobiol. Aging</i> 17:773-780 (1996)	<input type="checkbox"/>
14	MA et al., "Amyloid-Associated Proteins Alpha 1-Antichymotrypsin and Apolipoprotein E Promote Assembly of Alzheimer Beta-protein into Filaments," <i>Nature</i> 372:92-94 (1994)	<input type="checkbox"/>
15	NASLUND et al. "Characterization of Stable Complexes Involving Apolipoprotein E and the Amyloid Beta Peptide in Alzheimer's Disease Brain," <i>Neuron</i> 15:219-228 (1995)	<input type="checkbox"/>
16	SADOWSKI et al. "A Synthetic Peptide Blocking the Apolipoprotein E/Beta-Amyloid Binding Mitigates Beta-Amyloid Toxicity and Fibril Formation In Vitro and Reduces Beta-Amyloid Plaques in Transgenic Mice," <i>Am. J. Pathol.</i> 165:937-948 (2004)	<input type="checkbox"/>
17	SELKOE, "The Origins of Alzheimer Disease: A is for Amyloid," <i>JAMA</i> 283:1615-1617 (2000)	<input type="checkbox"/>
18	SHUVAEV and SIEST, "Interaction Between Human Amphipathic Apolipoproteins and Amyloid Beta-peptide: Surface Plasmon Resonance Studies," <i>FEBS Lett.</i> 383:9-12 (1996)	<input type="checkbox"/>
19	SIGURDSSON et al., "Immunization with a Nontoxic/Nonfibrillar Amyloid-Beta Homologous Peptide Reduces Alzheimer's Disease Associated Pathology in Transgenic Mice," <i>Am. J. Pathol.</i> 159:439-447 (2001)	<input type="checkbox"/>
20	SIGURDSSON et al., "In vivo Reversal of Amyloid Beta Lesions in Rat Brain," <i>J. Neuropath. Exp. Neurol.</i> 59:11-17 (2000)	<input type="checkbox"/>
21	SOTO et al., "Alzheimer's Beta-Amyloid Peptide is Conformationally Modified by Apolipoprotein E In Vitro," <i>Neuroreport</i> 7:721-725 (1996)	<input type="checkbox"/>
22	STRITTMATTER et al., "Apolipoprotein E: High-Avidity Binding to Beta-amyloid and Increased Frequency of Type 4 Allele in Late-onset Familial Alzheimer Disease," <i>Proc. Natl. Acad. Sci. (USA)</i> 90:1977-1981 (1993)	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /OC/

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10810919
Filing Date	2004-03-26
First Named Inventor	Wisniewski et al.
Art Unit	1649
Examiner Name	Olga N. Chernyshev
Attorney Docket Number	57953/1211

23	WISNIEWSKI et al., "Acceleration of Alzheimer's Fibril Formation by Apolipoprotein E In Vitro," Am. J. Pathol. 145:1030-1035 (1994) <input type="checkbox"/>
24	WISNIEWSKI and FRANGIONE, "Apolipoprotein E: A Pathological Chaperone Protein in Patients with Cerebral and Systemic Amyloid," Neurosci. Lett. 135:235-238 (1992) <input type="checkbox"/>
25	WISNIEWSKI et al., "Apolipoprotein E: Binding to Soluble Alzheimer's Beta-Amyloid," Biochem. Biophys. Res. Commun. 192:359-365 (1993) <input type="checkbox"/>
26	WISNIEWSKI et al., "Diffuse, Lake-like Amyloid-Beta Deposits in the Parvopyramidal Layer of the Presubiculum in Alzheimer Disease," Journal of Neuropathology & Experimental Neurology 57:674-683 (1998) <input type="checkbox"/>
27	ZLOKOVIC "Cerebrovascular Transport of Alzheimer's Amyloid Beta and Apolipoproteins J and E: Possible Anti-Amyloidogenic Role of the Blood-Brain Barrier," Life Sci. 59:1483-1497 (1996) <input type="checkbox"/>
28	ZLOKOVIC et al., "Brain Uptake of Circulating Apolipoproteins J and E Complexed to Alzheimer's Amyloid Beta," Biochem. Biophys. Res. Commun. 205:1431-1437 (1994) <input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/Olga Chernyshev/	Date Considered	03/04/2008
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /OC/